However, whether different mutations impact differently on the clinical phenotype and on the risk of myelodysplastic syndrome awaits further clinical and molecular characterization of PN patients, along with delineation of patients' clinical expressivity in distinct geographical areas and dissection of the biological function of the C16orf57 protein. This evidence concerns the gene USB1 and poikiloderma with neutropenia.